Ovid Therapeutics (1OT) Stock Overview
A biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1OT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.38 |
| 52 Week High | US$2.52 |
| 52 Week Low | US$0.26 |
| Beta | 0.19 |
| 1 Month Change | 19.60% |
| 3 Month Change | 9.17% |
| 1 Year Change | 653.16% |
| 3 Year Change | -21.71% |
| 5 Year Change | -22.73% |
| Change since IPO | -79.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1OT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | -0.6% | -0.5% |
| 1Y | 653.2% | 15.5% | -2.1% |
Return vs Industry: 1OT exceeded the German Biotechs industry which returned 17% over the past year.
Return vs Market: 1OT exceeded the German Market which returned 1.2% over the past year.
Price Volatility
| 1OT volatility | |
|---|---|
| 1OT Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 1OT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1OT's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 23 | Meg Alexander | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc. Fundamentals Summary
| 1OT fundamental statistics | |
|---|---|
| Market cap | €450.84m |
| Earnings (TTM) | -€21.07m |
| Revenue (TTM) | €6.23m |
Is 1OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1OT income statement (TTM) | |
|---|---|
| Revenue | US$7.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.12m |
| Other Expenses | US$31.19m |
| Earnings | -US$24.07m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -337.99% |
| Debt/Equity Ratio | 0% |
How did 1OT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 00:15 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ovid Therapeutics Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |